Last reviewed · How we verify

NCT05818748: VR-Ege

Effect Of Virtual Reality Distraction on Symptom Control and Anxiety in Children With Leukemia

Status unknown NA Last updated 19 April 2023
What this trial tests

NA trial testing virtual reality in Symptom Cluster in 40 participants. Status unknown.

Timeline
30 March 2023
Primary endpoint
30 March 2024
30 March 2024

Quick facts

Lead sponsorDokuz Eylul University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment40
Start date30 March 2023
Primary completion30 March 2024
Estimated completion30 March 2024
Sites2 locations across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Dokuz Eylul University

Who can join

Adults 7 to 18, any sex, with Symptom Cluster or Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aim to evaluate the effect of virtual reality distraction on symptom management and anxiety in children aged 7-18 years with leukemia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of virtual reality

Trials testing the same drug.

Other recruiting trials for Symptom Cluster

Currently open trials in the same condition.

Other Dokuz Eylul University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05818748.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing